We estimate that the Co-CEO and Director of Amylyx Pharmaceuticals, Inc. ($AMLX), Joshua Cohen, received a compensation of $2,719,807 in 2025. This is a decrease of -138.85% from an estimated $6,496,255 in 2024.
These estimates are based on a new DEF14A filing, filed with the SEC on April 23, 2026. Note that parsing errors may occur.
You can track $AMLX on Quiver Quantitative's $AMLX stock dashboard.
$AMLX Stock Insider Trading Activity
$AMLX Stock insiders have traded $AMLX stock on the open market 14 times in the past 6 months. Of those trades, 1 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $AMLX stock by insiders over the last 6 months:
- JOSHUA B COHEN (Co-Chief Executive Officer) has made 0 purchases and 4 sales selling 161,382 shares for an estimated $2,191,282.
- JUSTIN B. KLEE (Co-Chief Executive Officer) has made 0 purchases and 4 sales selling 161,403 shares for an estimated $2,190,776.
- KAREN FIRESTONE purchased 8,100 shares for an estimated $100,845
- GINA MAZZARIELLO (Chief Legal Officer) has made 0 purchases and 2 sales selling 6,867 shares for an estimated $98,867.
- CAMILLE L BEDROSIAN (Chief Medical Officer) sold 6,580 shares for an estimated $94,418
- JAMES M FRATES (Chief Financial Officer) has made 0 purchases and 2 sales selling 6,883 shares for an estimated $89,050.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AMLX Stock Hedge Fund Activity
We have seen 112 institutional investors add shares of $AMLX Stock stock to their portfolio, and 72 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 5,139,212 shares (+45.2%) to their portfolio in Q4 2025, for an estimated $62,081,680
- POINT72 ASSET MANAGEMENT, L.P. removed 2,455,066 shares (-88.0%) from their portfolio in Q4 2025, for an estimated $29,657,197
- JANUS HENDERSON GROUP PLC added 1,929,639 shares (+76.1%) to their portfolio in Q4 2025, for an estimated $23,310,039
- BLACKROCK, INC. added 1,913,739 shares (+26.8%) to their portfolio in Q4 2025, for an estimated $23,117,967
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,900,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $22,952,000
- COMMODORE CAPITAL LP added 1,574,522 shares (+38.6%) to their portfolio in Q4 2025, for an estimated $19,020,225
- FRANKLIN RESOURCES INC added 1,200,096 shares (+inf%) to their portfolio in Q4 2025, for an estimated $14,497,159
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$AMLX Stock Analyst Ratings
Wall Street analysts have issued reports on $AMLX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 03/03/2026
- HC Wainwright & Co. issued a "Buy" rating on 11/07/2025
To track analyst ratings and price targets for $AMLX Stock, check out Quiver Quantitative's $AMLX forecast page.
$AMLX Stock Price Targets
Multiple analysts have issued price targets for $AMLX recently. We have seen 5 analysts offer price targets for $AMLX in the last 6 months, with a median target of $21.0.
Here are some recent targets:
- Andrew S. Fein from HC Wainwright & Co. set a target price of $34.0 on 03/25/2026
- Seamus Fernandez from Guggenheim set a target price of $30.0 on 03/19/2026
- James Condulis from Stifel set a target price of $21.0 on 03/03/2026
- Geoff Meacham from B of A Securities set a target price of $19.0 on 02/20/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
